Airway technology product developer Rhinomed (ASX: RNO) has secured US Food and Drug Administration and Australian Therapeutic Goods Administration registration for its Pronto vapour release technology.
The Pronto rechargeable vapour release unit has now been approved as a class I medical device with both countries’ regulators.
Based on Rhinomed’s existing BreatheAssist stenting nasal dilator technology, Pronto comprises the Airstream release system that allows a continuous release of an essential oil blend into the nasal airstream over a set period.
When incorporating the stenting technology into the Pronto vapour release unit, users are provided with a unique dual action device that improves nasal airflow and offers a soothing blend of pure essential oils that are traditionally known to help clear a stuffy nose or assist with enhanced natural sleep. More…
Sounds like B/S to me! Blowing some lavender oil, or such like, up your nose as you sleep!
They had a bit of a volume spike as the news was released but it appeared to be selling not buying as illustrated by Twiggs weekly Money Flow indicator.
Be the first to comment